Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models

Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models

Malignant gliomas are the most common primary central nervous system tumor in adults. Despite current therapeutics, these tumors are associated with poor prognosis and a median survival of 16 to 19 months. This highlights the need for innovative treatments for this incurable disease. Rac1 has long b...

Full description

Bibliographic Details
Main Authors: Georgina A. Cardama, Julian Maggio, Lucas Valdez Capuccino, Nazareno Gonzalez, Valentina Matiller, Hugo H. Ortega, German R. Perez, Ignacio A. Demarco, Eduardo Spitzer, Daniel E. Gomez, Pablo Lorenzano Menna, Daniel F. Alonso
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
Rac1 inhibitor
glioma
1A-116
Online Access:https://www.mdpi.com/2072-6694/14/19/4810

Internet

https://www.mdpi.com/2072-6694/14/19/4810

Similar Items